Salbutamol

Section: 25. Medicines acting on the respiratory tract ➤ 25.1. Antiasthmatic and medicines for chronic obstructive pulmonary disease

- **Indication**: Chronic obstructive pulmonary disease [ICD11 code: CA22]
- **INN**: Salbutamol
- **Medicine type**: Chemical agent
- **List type**: Core
- **Formulations**:
  - Parenteral > General injections > IV: 50 µg per mL in 5 mL ampoule (as sulfate)
  - Respiratory > Inhalation > aerosol: 100 µg per dose (as sulfate) ; 100 µg per dose (as sulfate) metered-dose inhaler
  - Respiratory > Inhalation > solution: 5 mg per mL (as sulfate) for use in nebulizers
- **EML status history**:
  - First added in 2003 (TRS 920)
  - Changed in 2009 (TRS 958)
  - Changed in 2011 (TRS 965)
  - Changed in 2021
- **Sex**: All
- **Age**: Adolescents and adults
- **Therapeutic alternatives**: terbutaline (ATC codes: R03CC03)
- **Patent information**: Patents have expired in most jurisdictions
  [Read more about patents.](#)
- **Wikipedia**: [Salbutamol](#)
- **DrugBank**: [Salbutamol](#)

**Summary of evidence and Expert Committee recommendations**

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended terbutaline be specified as a therapeutic alternative under the square box listing for salbutamol on the EML for this indication.